Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis

Drugs under Experimental and Clinical Research

Volumn 29, Issue 1, 2003, Pages 15-23

  Bae, M ^a   Cho, S ^a   Song, J ^a   Lee, G Y ^a   Kim, K ^a   Yang, J ^b   Cho, K ^b   Kim, S Y ^b   Byun, Y ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GELATINASE A; GELATINASE B; POLY(ETHYLENE GLYCOL)METHYL ETHER GLYCYLPROLYLLEUCYLGLYCYLVALINE DOXORUBICIN CONJUGATE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CIRCULATION TIME; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME LOCALIZATION; ENZYME RELEASE; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; LIFESPAN; MICELLE; MOUSE; NONHUMAN; SOLID TUMOR; ZYMOGRAPHY;

ANGIOGENESIS INHIBITORS; ANIMALS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICELLES; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PRODRUGS; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0037707304     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol., 189, 300, 1999.
2. Stearns M.E., Wang M Type IV collagenase (M(r) 72,000) expression in human prostate Benign and malignant tissues. Cancer Res., 53, 878, 1993.
3. Davies B., Waxman J., Wasan H., et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53, 5365, 1993.
4. Bremer C., Tung C.H., Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat. Med., 7, 743, 2001
5. Kratz F., Drevs J., Bing G., et al Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Bioorg. Med. Chem. Lett., 11, 2001, 2001.
6. Seltzer J.L., Akers K.T., Weingarten H., Grant G.A., McCourt D.W., Eisen A.Z Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. J. Biol. Chem. 265, 20409, 1990.
7. Netzel-Arnett S., Sang Q., Moore W.G.I., Navre M., Birkedal-Hansen H., Van Wart H.E. Comparative sequence specificities of human 72- and 92-kDa gelatinases (Type IV collagenases) and PUMP (Matrilyxin). Biochemistry, 32, 6427, 1993.
8. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 351, 1994.
9. O'Reilly M.S., Boenm T., Shing Y., et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277, 1997.
10. Fidler I.J. Rationale and methods for the use of nude mice to study in biology and therapy of human cancer metastasis. Cancer Metastasis Rev., 5, 29, 1986.
11. Makowski G.S., Ramsby M.L. Calibrating gelatin zymograms with human gelatinase standards. Anal. Biochem., 236, 353, 1996.
12. Koyama H., Iwata H., Kuwabara Y., Iwase H., Kobayashi S., Fujii Y. Gelatinolytic activity of matrix metalloproteinases-2 and -9 in oesophageal carcinoma, a study using in situ zymography. Eur. J. Cancer, 36, 2164, 2000.
13. Ikeda M., Maekawa R., Tanaka H., et al. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor. Application of film in situ zymography. Clin. Cancer Res., 6, 3290, 2000.
14. Kaneyoshi T., Nakatsukasa H., Higashi T., et al Actual invasive potential of human hepatocellular carcinoma revealed by in situ gelatin zymography. Clin. Cancer Res., 7, 4027, 2001
15. Zalipsky S., Barany G. Facile synthesis of a hydroxy-w-carboxymethylpolyethylene oxide. J Bioact. Compat. Polym., 5, 227, 1990.
16. Polette M., Birembaut P. Membrane-type metalloproteinases in tumor invasion. Int. J. Biochem. Cell Biol., 30, 1195, 1998.
17. Maeda H., Wu J., Sawa T., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control Release, 65, 271, 2000